Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Immunoperoxidase techniques were used to obtain information about the possible presence of serum factors in senile plaques. We found only in plaques consisting of an amyloid core surrounded by a corona of degenerating neurites small amounts of IgG and light chains (kappa and lambda). These immunoglobulins were principally localized in the corona and not in the central amyloid core. Further it was found that all plaques contain the complement factors C1q, C3b, C3c, C3d and C4. Senile plaques lacked C5, C3 pro-activator and properdin. The possible significance of these findings in the genesis of the senile plaques and amyloid formation is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activated microglia along with immunoglobulins and complement components are closely associated with Aβ deposits in brains from AD patients and AD mouse models (58)(59)(60)(61)(62).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [58]
Citations
Cites
Histochemistry: Theoretical and Applied
(1953) · Journal of the American Medical Association · doi:10.1001/jama.1953.02940280072039 · Cited by 7,021
ON THE BINDING OF CONGO RED BY AMYLOID
PUCHTLER, H., SWEAT, F., & LEVINE, M. (1962) · Journal of Histochemistry & Cytochemistry · doi:10.1177/10.3.355 · Cited by 1,128
Peroxidase labelled antibody and Fab conjugates with enhanced intracellular penetration
Avrameas, S., & Ternynck, T. (1971) · Immunochemistry · doi:10.1016/0019-2791(71)90395-8 · Cited by 862
Kaplan, M. H., & Volanakis, J. E. (1974) · PubMed · Cited by 563
Glynn, L. E. (1981) · PubMed Central · Cited by 412
Interaction of C-Reactive Protein Complexes with the Complement System
Kaplan, M. H., & Volanakis, J. E. (1974) · The Journal of Immunology · doi:10.4049/jimmunol.112.6.2135 · Cited by 405
ALZHEIMER'S DISEASE AND RELATED DISORDERS
Raskind, M. A., & Peskind, E. R. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70341-2 · Cited by 161
Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques
Ishii, T., & Haga, S. (1976) · Acta Neuropathologica · doi:10.1007/bf00685368 · Cited by 142
Ishii, T., Haga, S., & Shimizu, F. (1975) · Acta Neuropathologica · doi:10.1007/bf00689569 · Cited by 110
Research works printed but not linked: 6
- Boorsma DM, Streefkerk JG (1978) Improved method for separation of peroxidase conjugates. In: Knapp W, Holubar, K, Wick G (eds) Immunofluorescence and related staining techniques. Elsevier-North Holland Biochemical Press Amsterdam, pp 225?235
- Boorsma DM, Streefkerk JG (1976a) Some aspects of the preparation, analysis and use of peroxidase-antibody conjugates in immunohistochemistry. In: Pecters H (ed) Protides of the biological fluids, vol 24. Pergamon Press, Oxford, pp 795?802
- Davis BJ, Ornstein L (1959) High resolution enzyme localization with a new diazo reagent, ?hexazonium Pararosaniline?. J Histochem Cytochem 7:297?298
- Divry P (1927) Etude histochimique des plaques seniles. J Belge Nerol 27:643?657
- Stam FC (1965) Histochemistry of the senile involution of the brain. In: Vtn Int Congr Neuropathol Proc. Excerpta Medica, Amsterdam, pp 513?517
- Wigboldus JM (1959) Over de aard en genese van de plaques seniles. Thesis. Dijkstra's Drukkerij N.V., Groningen
Cited by
Items 201–300 of 453
Rozemüller, A. J. M., Eikelenboom, P., Kamphorst, W., & Stam, F. C. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80085-x · Cited by 63
Self-citationRasmussen, K. L., Nordestgaard, B. G., Frikke‐Schmidt, R., & Nielsen, S. F. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.223 · Cited by 53
“All of these mechanisms evolve around the central metabolism of amyloid-b and tau [66,67], and the updated Alzheimer hypothesis presented in this article may potentially be linked, as complement factors are found in amyloid plaques and as tau is an activator of the complement system [30,34].”
BackgroundHaga, S., Aizawa, T., Ishii, T., & Ikeda, K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13040-8 · Cited by 53
History of Innate Immunity in Neurodegenerative Disorders
McGeer, P. L., & McGeer, E. G. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00077 · Cited by 51
“Eikelenboom and Stam (1982) were the first to report the presence of complement factors in AD senile plaques.”
BackgroundImaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S., & Rosa-Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 52
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobricic, V., Bos, I., Vos, S., Tsolaki, M., Verhey, F., Popp, J., Martinez-Lage, P., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00628-z · Cited by 50
Molecular and cellular mediators of Alzheimer's disease inflammation
Strohmeyer, R., & Rogers, J. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3118 · Cited by 51
Antibodies to Cholinergic Neurons in Alzheimer's Disease
Chapman, J., Bachar, O., Korczyn, A. D., Wertman, E., & Michaelson, D. M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01063.x · Cited by 51
Popović, M., Caballero-Bleda, M., Puelles, L., & Popović, N. (1998) · International Journal of Neuroscience · doi:10.3109/00207459809003341 · Cited by 50
Activated microglial cells and complement factors are unrelated to cortical Lewy bodies
Rozemuller, A. J. M., Eikelenboom, P., Theeuwes, J. W., Jansen Steur, E. N. H., & de Vos, R. A. I. (2000) · Acta Neuropathologica · doi:10.1007/s004010000225 · Cited by 50
Self-citationSulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning
Lampert-Etchells, M., McNeill, T. H., Laping, N. J., Zarow, C., Finch, C. E., & May, P. C. (1991) · Brain Research · doi:10.1016/0006-8993(91)91520-b · Cited by 50
Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease
Boon, B. D. C., Hoozemans, J. J. M., Lopuhaä, B., Eigenhuis, K. N., Scheltens, P., Kamphorst, W., Rozemuller, A. J. M., & Bouwman, F. H. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1180-y · Cited by 48
“Multiple studies have reported complement proteins to be associated with amyloid-beta deposits [19, 39].”
Background(1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.9.937 · Cited by 49
Smyth, M. D., Cribbs, D. H., Tenner, A. J., Shankle, W. R., Dick, M. B., Kesslak, J. P., & Cotman, C. W. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)00055-7 · Cited by 50
A functional role for corpora amylacea based on evidence from complement studies
Singhrao, S. K., Morgan, B. P., Neal, J. W., & Newman, G. R. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90024-1 · Cited by 47
BioAge: Toward a multi-determined, mechanistic account of cognitive aging
DeCarlo, C. A., Tuokko, H. A., Williams, D., Dixon, R. A., & MacDonald, S. W. S. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.09.003 · Cited by 53
“Correspondingly, inflammatory molecules have been associated with amyloid deposits in the brain (Eikelenboom and Stam, 1982).”
BackgroundShen, Y., Sullivan, T., Lee, C., Meri, S., Shiosaki, K., & Lin, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00346-1 · Cited by 46
A review of human diseases caused or exacerbated by aberrant complement activation
McGeer, P. L., Lee, M., & McGeer, E. G. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.017 · Cited by 49
Olsen, I., & Singhrao, S. K. (2019) · Journal of Oral Microbiology · doi:10.1080/20002297.2019.1676486 · Cited by 58
“through the classical complement pathway activation and receptors for specific (C3a, C5a) opsonins [11,12,56,57].”
BackgroundTREATMENT OF ALZHEIMER'S DISEASE
Grundman, M., & Thal, L. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70227-9 · Cited by 47
Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease
Brachova, L., Lue, L., Schultz, J. J., Rashidy, T. E., & Rogers, J. (1993) · Molecular Brain Research · doi:10.1016/0169-328x(93)90097-9 · Cited by 46
What can imaging tell us about cognitive impairment and dementia?
Narayanan, L., & Murray, A. D. (2016) · World Journal of Radiology · doi:10.4329/wjr.v8.i3.240 · Cited by 48
Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer’s Disease
Li, L., Zhang, W., Cheng, S., Cao, D., & Parent, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8253-1 · Cited by 45
“intracellular adhesion molecule-1, α2-macroglobulin, Creactive protein, serum amyloid P component, and heparan sulphate proteoglycans, have been identified in senile plaques and neurofibrillary tangles [33–36].”
Targeting complement in neurodegeneration: challenges, risks, and strategies
Zelek, W. M., & Morgan, B. P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.006 · Cited by 43
The role of complement in neurological and neuropsychiatric diseases
Morgan, B. P. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1074039 · Cited by 44
Carter, C. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.003 · Cited by 47
IL-1 and anti-inflammatory drugs modulate A β cytotoxicity in PC12 cells
Fágárásan, M. O., & Aisen, P. S. S. (1996) · Brain Research · doi:10.1016/0006-8993(96)00259-4 · Cited by 43
Plasma Levels of Complement 4a Protein are Increased in Alzheimer's Disease
Bennett, S. J., Grant, M. M., Creese, A. J., Mangialasche, F., Cecchetti, R., Cooper, H. J., Mecocci, P., & Aldred, S. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318239dcbd · Cited by 43
Neuroprotective versus Neuroinflammatory Roles of Complement: From Development to Disease
Kanmogne, M., & Klein, R. S. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.003 · Cited by 42
The role of the complement system in CNS inflammatory diseases
Stahel, P. F., & Barnum, S. R. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.3.445 · Cited by 44
Sigfridsson, E., Marangoni, M., Johnson, J. A., Hardingham, G. E., Fowler, J. H., & Horsburgh, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-30675-4 · Cited by 41
Activated microglia and cerebral amyloid deposits in alzheimer's disease
Rozemüller, A. J. M., van der Valk, P., & Eikelenboom, P. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80050-u · Cited by 42
Self-citationFocal Inflammation in the Brain: Role in Alzheimer's Disease
Cooper, N. R., Bradt, B. M., O’Barr, S. A., & Yu, J. X. (2000) · Immunologic Research · doi:10.1385/ir:21:2-3:159 · Cited by 41
Aging, Amyloid, and Alzheimer's Disease
Selkoe, D. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202209 · Cited by 41
Eikelenboom, P., Hack, C. E., Kamphorst, W., & Rozemuller, J. M. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80044-l · Cited by 40
Self-citationThe importance of inflammatory mechanisms for the development of Alzheimer’s disease
Eikelenboom, P., & Veerhuis, R. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00022-4 · Cited by 46
Self-citationThe role of the acute-phase protein α1-antichymotrypsin in brain dysfunction and injury
Abraham, C. R. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80047-o · Cited by 40
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 46
(Re)building the nervous system: A review of neuron–glia interactions from development to disease
Demmings, M. D., Chagas, L. D. S., Traetta, M. E., Rodrigues, R. S., Acutain, M. F., Barykin, E. P., Datusalia, A. K., German‐Castelan, L., Mattera, V. S., Mazengenya, P., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16258 · Cited by 49
“More specifically, examination of post-mortem human brains has demonstrated that complement proteins are associated with amyloid-rich plaques in AD (Eikelenboom & Stam, 1982 ) and α - synuclein inclusions in PD (Loeffler et al., 2006; Yamada et al., 1992 ).”
Novel approaches for immunotherapeutic intervention in Alzheimer's disease
Vasilevko, V., & Cribbs, D. H. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.019 · Cited by 39
Sun, Q., Hampel, H. J., Blennow, K., Lista, S., Levey, A. I., Tang, B., Li, R., & Shen, Y. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140177 · Cited by 47
Complement Activation in Capillary Cerebral Amyloid Angiopathy
Matsuo, K., Shindo, A., Niwa, A., Tabei, K.-I., Akatsu, H., Hashizume, Y., Akiyama, H., Ayaki, T., Maki, T., Sawamoto, N., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000486091 · Cited by 37
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 45
“In AD, microglia and astrocytes become activated and cluster around Aβ plaques, where they secrete inflammatory signals and phagocytize the debris from plaques and injured cells (Eikelenboom and Stam, 1982; reviewed in Wyss-Coray, 2006).”
BackgroundPetrushina, I., Ghochikyan, A., Mkrtichyan, M., Mamikonyan, G., Movsesyan, N., Ajdari, R., Vasilevko, V., Karapetyan, A., Lees, A., Agadjanyan, M. G., et al. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-42 · Cited by 38
“If so, one potential culprit in the microhemorrhage may be the activation of the complement cascade by antibody-Aβ immune complexes at sites of CAA [89,90].”
Fekete, C., Vastagh, C., Dénes, Á., Hrabovszky, E., Nyíri, G., Kalló, I., Liposits, Z., & Sárvári, M. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.046 · Cited by 43
Ultrastructural Changes of Blood Vessels in the Cerebral Cortex in Alzheimer's Disease
Higuchi, Y., Miyakawa, T., Shimoji, A., & Katsuragi, S. (1987) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1987.tb00414.x · Cited by 37
Sokolova, D., Childs, T., & Hong, S. Y. (2021) · Faculty Reviews · doi:10.12703/r/10-19 · Cited by 39
Choucair-Jaafar, N., Laporte, V., Levy, R., Poindron, P., Lombard, Y., & Gies, J.-P. (2011) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00811.x · Cited by 35
Potter, H. (1998) · Frontiers in Bioscience · doi:10.2741/a290 · Cited by 35
Blood‐Brain Barrier Abnormalities in Alzheimer's Diseasea
HARIK, S. I., & KALARIA, R. N. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00189.x · Cited by 35
RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome
Hamlett, E. D., Hjorth, E., Ledreux, A., Gilmore, A., Schultzberg, M., & Granholm, A. C. (2020) · Glia · doi:10.1002/glia.23779 · Cited by 34
“…specialized proresolving mediators, Ts65Dn 1 | INTRODUCTION Neuroinflammation accompanies the neurodegeneration of Alzheimer's disease (AD) (Eikelenboom & Stam, 1982) and is believed to promote secondary molecular pathogenesis, by an intimate relationship with both β-amyloid and…”
BackgroundBoyett, K. W., DiCarlo, G., Jantzen, P. T., Jackson, J., O’Leary, C., Wilcock, D. M., Morgan, D., & Gordon, M. N. (2003) · Neurochemical Research · doi:10.1023/a:1021600212829 · Cited by 37
“Complement proteins were initially found to be involved in Alzheimer’s disease (AD) with the discovery of their co-localization with A b deposits in human AD brain tissue by (1).”
BackgroundAmyloids: The History of Toxicity and Functionality
Yakupova, E. I., Bobyleva, L. G., Shumeyko, S. A., Vikhlyantsev, I. M., & Bobylev, A. G. (2021) · Biology · doi:10.3390/biology10050394 · Cited by 39
Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease
O’Banion, M. K., & Finch, C. E. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00102-9 · Cited by 33
Karring, H., Poulsen, E. T., Runager, K., Thøgersen, I. B., Klintworth, G. K., Højrup, P., & Enghild, J. J. (2013) · PubMed Central · Cited by 36
Propionibacterium acnes in the cortex of patients with Alzheimer's disease
Kornhuber, H. H. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02274902 · Cited by 32
A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques
Verbeek, M. M., Otte‐Höller, I., Wesseling, P., Nostrand, W. E. V., Sorg, C., de Waal, R. M. W., & Ruiter, D. J. (1995) · Acta Neuropathologica · doi:10.1007/bf00294811 · Cited by 32
Ishii, T., Haga, S., & Kametani, F. (1988) · Springer eBooks · doi:10.1007/978-3-642-46634-2_3 · Cited by 32
Proitsi, P., Lupton, M. K., Dudbridge, F., Tsolaki, M., Hamilton, G., Daniilidou, M., Pritchard, M., Lord, K., Martin, B. M., Craig, D., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.036 · Cited by 38
“, 2011), it has been widely known since the early 80s, through immunohistochemical (Eikelenboom and Stam, 1982; Eikelenboom et al., 1989; McGeer et al., 1989; Rogers et al., 1992) and transgenic knockout mice studies (Fonseca et al.”
BackgroundINFLAMMATION AND ALZHEIMER'S DISEASE
Gupta, A., & Pansari, K. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb11394.x · Cited by 31
Jiang, S., & Bhaskar, K. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161123 · Cited by 30
“The amyloid-β (Aβ) plaques were shown to contain complement factors [30], and the classical complement pathway was observed to be activated in the AD patient brain [31].”
Jeong, H., Kim, O. J., Oh, S., Lee, S., Lee, H. A. R., Lee, K. O., Lee, B.-Y., & Kim, N. K. (2021) · Stem Cells International · doi:10.1155/2021/5548630 · Cited by 36
“In fl ammation-related proteins, complement factors, and immunoglobulins were found in the senile plaques of patients with AD [76, 79].”
Binding of Human Proteins to Amyloid-β Protofibrils
Rahman, M. M., Zetterberg, H., Lendel, C., & Härd, T. (2014) · ACS Chemical Biology · doi:10.1021/cb5008663 · Cited by 41
A new method to classify amyloid fibril proteins
Kitamoto, T., Tateishi, J., Hikita, K., Nagara, H., & Takeshita, I. (1985) · Acta Neuropathologica · doi:10.1007/bf00687812 · Cited by 30
Antibodies To Cholinergic Cell Bodies In Alzheimer’s Disease
Chapman, J., Korczyn, A. D., Hareuveni, M., & Michaelson, D. M. (1986) · Advances in behavioral biology · doi:10.1007/978-1-4613-2179-8_40 · Cited by 30
Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 30
Huang, N., Li, Y., Zhou, Y., Zhou, Y., Feng, F., Shi, S., Ba, Z., & Luo, Y. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.03.001 · Cited by 30
“early as 1982, inflammation-related proteins, complement factors, and immunoglobulins were found in the senile plaques of AD patients [4].”
BackgroundLee, M., Guo, J., Schwab, C., McGeer, E. G., & McGeer, P. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.005 · Cited by 31
“Complement activation, including formation of the MAC, has been clearly identified in some of the most prevalent of these age-related disorders, including Alzheimer disease (AD) (Eikelenboom and Stam, 1982; McGeer et al., 1989; Rogers et al., 1992; Shen et al., 2001), Parkinson disease (PD) (Yamada et al.”
BackgroundIkeda, T., Yamamoto, K., Takahashi, K., & Yamada, M. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb05573.x · Cited by 28
The Complement System in Central Nervous System Diseases
Rus, H., & Niculescu, F. I. (2001) · Immunologic Research · doi:10.1385/ir:24:1:79 · Cited by 28
Immune actions in the nervous system: A brief review with special emphasis on Aalzheimer's disease
Rogers, J., & Luber‐Narod, J. (1988) · Drug Development Research · doi:10.1002/ddr.430150214 · Cited by 27
Role of Apolipoprotein E in Alzheimer’s Disease
Zannis, V. I., Zanni, E. E., Makrides, S. C., Kardassis, D., & Aleshkov, S. B. (1998) · Springer eBooks · doi:10.1007/978-1-4899-0133-0_13 · Cited by 27
Effects of C‐reactive protein and pentosan polysulphate on human complement activation
Klegeris, A., Singh, E. A., & McGeer, P. L. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01425.x · Cited by 26
A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes
Heininger, K. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199912)14:8<525::aid-hup140>3.0.co;2-t · Cited by 30
Inhibition of C1q-β-amyloid binding protects hippocampal cells against complement mediated toxicity
Sárvári, M., Vágó, I., Wéber, C. S., Nagy, J., Gál, P., Mák, M., Kósa, J. P., Závodszky, P., & Pázmány, T. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00040-7 · Cited by 27
“Complement synthesis is up-regulated in AD brain (Yasojima et al., 1999) and complement proteins, including C1q are associated with senile plaques, one of the pathological hallmarks of AD (Eikelenboom and Stam, 1982; Stoltzner et al., 2000).”
BackgroundChapter 21. Alzheimer's Disease: Current Therapeutic Approaches
John, V., Lieberburg, I. M., & Thorsett, E. D. (1993) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60891-x · Cited by 26
Rozemüller, A. J. M., Bots, G. T. A. M., Roos, R. A. C., & Eikelenboom, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90087-n · Cited by 27
Self-citationComplement activation by cross-linked truncated and chimeric full-length β-amyloid
Cribbs, D. H., Velázquez, P., Soreghan, B. A., Glabe, C. G., & Tenner, A. J. (1997) · Neuroreport · doi:10.1097/00001756-199711100-00009 · Cited by 26
Knowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 27
Dujardin, B. C. G., Driedijk, P. C., Roijers, A. F. M., & Out, T. A. (1985) · Journal of Immunological Methods · doi:10.1016/0022-1759(85)90024-9 · Cited by 25
Complements, microglial cells and amyloid fibril formation
Ishii, T., & Haga, S. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80043-k · Cited by 25
Presenilin-1 is associated with Alzheimer's disease amyloid.
Wısnıewskı, T., Dowjat, W. K., Permanne, B., Palha, J. A., Kumar, A., Gallo, G., & Frangione, B. (1997) · Europe PMC (PubMed Central) · Cited by 27
Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 26
Proteomics analysis of methylglyoxal‐induced neurotoxic effects in SH‐SY5Y cells
Li, G., Chang, M., Jiang, H., Xie, H., Dong, Z., & Hu, L. (2010) · Cell Biochemistry and Function · doi:10.1002/cbf.1714 · Cited by 22
Immune Responses in Brains of Alzheimer's and Parkinson's Disease Patients: Hypothesis and Reality
McRae‐Degueurce, A., & Dahlström, A. B. (1992) · Reviews in the Neurosciences · doi:10.1515/revneuro.1992.3.2.79 · Cited by 23
Ultrastructural heterogeneity in cerebral amyloid of Alzheimer's disease
Powers, J. M., & Skeen, J. T. (1988) · Acta Neuropathologica · doi:10.1007/bf00689601 · Cited by 22
“Evidence for both local, probably neuronal, [1, 4, 5, 11, 26, 39-41] and serum [10, 14, 15, 19, 25] origins have been presented.”
BackgroundFabrizi, C., Businaro, R., Lauro, G. M., Starace, G., & Fumagalli, L. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6978 · Cited by 14
Immunological Markers and Neuropathological Lesions in Alzheimer’s Disease
Pouplard-Barthelaix, A. (1988) · Springer eBooks · doi:10.1007/978-3-642-46634-2_2 · Cited by 22
Immunological Aspects of Alzheimer??s Disease: Therapeutic Implications
Hoozemans, J. J. M., Rozemüller, A. J. M., Veerhuis, R., & Eikelenboom, P. (2001) · BioDrugs · doi:10.2165/00063030-200115050-00004 · Cited by 23
“plaques reveal the presence of an inflammatory process.[8-10] Second, polymorphisms of acute-phase”
BackgroundSelf-citationEvans, P. H., Klinowski, J., & Yano, E. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90213-i · Cited by 22
C1q Regulates Horizontal Cell Neurite Confinement in the Outer Retina
Burger, C. A., Jiang, D., Li, F., & Samuel, M. A. (2020) · Frontiers in Neural Circuits · doi:10.3389/fncir.2020.583391 · Cited by 20
Molecular Regulation Mechanism of Microglial Autophagy in the Pathology of Alzheimer's Disease
Ou-Yang, P., Cai, Z., & Zhang, Z.-H. (2023) · Aging and Disease · doi:10.14336/ad.2023.0106 · Cited by 28
“proteins, were enriched in the senile plaques of AD patients [2].”
Conservation of the Amyloid Interactome Across Diverse Fibrillar Structures
Juhl, D. W., Risør, M. W., Scavenius, C., Rasmussen, C. B., Otzen, D. E., Nielsen, N. C., & Enghild, J. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-40483-z · Cited by 19
Sulfated Glycoprotein‐2: An Emerging Molecular Marker for Neurodegeneration
May, P. C. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb18303.x · Cited by 21
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
“However, it was shown that A β plaques correlate with neuroinflammation and neuritic dystrophy (Dickson, 1997; Eikelenboom & Stam, 1982; Griffin et al., 1989; McGeer & McGeer, 2013; Tsai et al., 2004).”
BackgroundAlzheimer's Disease Neuropathology: Current Status of Interpretation of Lesion Developmenta
Wísniewski, H. M., & Węgiel, J. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb27463.x · Cited by 20
Dahlström, A. B., McRae‐Degueurce, A., Polinsky, R. J., Nee, L. E., Sadasivan, B., & Ling, E. A. (1994) · Molecular Neurobiology · doi:10.1007/bf02816104 · Cited by 19
Complement therapeutics in neurodegenerative diseases
Zelek, W. M., & Tenner, A. J. (2025) · Immunobiology · doi:10.1016/j.imbio.2025.153089 · Cited by 21
“3) (Eikelenboom and Stam, 1982; Fatoba et al., 2022).”
Yadav, V., Mythri, C., & Kumarasamy, M. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100048 · Cited by 26
Strategies for Inhibition of Complement Activation in the Treatment of Neurodegenerative Diseases
Spiegel, K., Emmerling, M. R., & Barnum, S. R. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-473-3_5 · Cited by 21
Metadata
- Authors
- Eikelenboom, P., & Stam, F. C.
- Affiliations
- Vrije Universiteit Amsterdam (NL)
- ORCID
- Eikelenboom, P.
- Venue
- Acta Neuropathologica
- Published
- 1982
- Volume
- 57
- Issue
- 2-3
- Pages
- 239-242
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2312933856
- Cited by
- 454
- References
- 24
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 8 · 2021: 12 · 2020: 23 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 9 · 2015: 7 · 2014: 16 · 2013: 7 · 2012: 11
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- amyloid plaques, Alzheimer's disease, immunoglobulins, complement proteins, amyloid core, neurite degeneration, IgG, kappa light chain, lambda light chain, C1q, C3b, C3c, C3d, C4, C5, properdin, amyloid fibril formation
- MeSH terms
- Alzheimer Disease, Amyloid, Cerebral Cortex, Complement System Proteins, Dementia, Humans, Immunoglobulin G, Immunoenzyme Techniques, Immunoglobulins, Immunoglobulin Fc Fragments, Immunoglobulin gamma-Chains
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.